CLINICAL TRIALS PROFILE FOR TEKTURNA

505(b)(2) Clinical Trials for Tekturna

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT01417104 ↗	Aliskiren Effect on Aortic Plaque Progression	Terminated	Novartis	Phase 2/Phase 3	2009-10-01	This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of the aortic wall. Aliskiren is an FDA approved drug for hypertension but in this study is used for a new indication. Recent studies with animals have shown that Aliskiren therapy reduces the atherosclerotic plaque. Therefore, in this study, the investigators would like to evaluate whether the investigational drug Aliskiren, which is not FDA approved for this indication has the same beneficial effects in people with atherosclerotic disease.
New Indication	NCT01417104 ↗	Aliskiren Effect on Aortic Plaque Progression	Terminated	Ohio State University	Phase 2/Phase 3	2009-10-01	This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of the aortic wall. Aliskiren is an FDA approved drug for hypertension but in this study is used for a new indication. Recent studies with animals have shown that Aliskiren therapy reduces the atherosclerotic plaque. Therefore, in this study, the investigators would like to evaluate whether the investigational drug Aliskiren, which is not FDA approved for this indication has the same beneficial effects in people with atherosclerotic disease.
New Indication	NCT01417104 ↗	Aliskiren Effect on Aortic Plaque Progression	Terminated	Sanjay Rajagopalan	Phase 2/Phase 3	2009-10-01	This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of the aortic wall. Aliskiren is an FDA approved drug for hypertension but in this study is used for a new indication. Recent studies with animals have shown that Aliskiren therapy reduces the atherosclerotic plaque. Therefore, in this study, the investigators would like to evaluate whether the investigational drug Aliskiren, which is not FDA approved for this indication has the same beneficial effects in people with atherosclerotic disease.

All Clinical Trials for Tekturna

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00627861 ↗	Combined Renin Inhibition/Beta-blockade	Terminated	The Rogosin Institute	N/A	2008-11-01	Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat hypertension by blocking the RAAS system have been developed. However, the kidney responds to these drug treatments by producing greater amounts of renin. This high level of renin can reduce the effectiveness of some of these medications, ultimately causing the blood pressure to rise. This is one reason why blood pressure can be difficult to control in a certain percentage of patients. The hypothesis to be tested in the proposed study is that beta-adrenergic blockade (β-blockade), when superimposed upon aliskiren, a drug that competitively inhibits plasma renin activity (PRA) but stimulates the release of renin by the kidneys (plasma renin concentration [PRC]), can suppress the reactive increase in PRC that occurs during aliskiren monotherapy. The primary aim of this study is to measure plasma renin concentration (PRC) and plasma renin activity (PRA) levels during renin inhibition with aliskiren and combined renin inhibition/β-blocker treatment to determine whether the addition of a β-blocker attenuates the rise in plasma renin concentration (PRC). A secondary aim is to determine whether combined treatment further suppresses PRA and blood pressure.
NCT00773084 ↗	Aliskiren and Renin Inhibition in Diastolic Heart Failure	Withdrawn	Texas Tech University Health Sciences Center	N/A	2008-09-01	This study is being conducted to compare the effects that 2 different combinations of heart failure medications have on the levels of certain blood markers which cause and/or worsen heart failure. Additionally, the investigators will investigate any differences that may exist between Hispanics and Non-Hispanics. The investigators hope to find that Hispanic Americans will have a greater response to this new regimen compared to non-Hispanic Americans.
NCT00818779 ↗	Direct Renin Inhibition Effects on Atherosclerotic Biomarkers	Completed	Texas Tech University Health Sciences Center	Phase 4	2008-01-01	The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.
NCT00961207 ↗	Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients	Terminated	John H. Stroger Hospital	Phase 4	2009-08-01	Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320 mg and either enalapril 40 mg or benazepril 40 mg daily, or losartan 100mg), persistent albuminuria reflects further additional RAAS activation. Microvascular renal disease due to increased RAAS activation may be more effectively treated with triple blockade by the addition of a direct renin inhibitor (DRI) Aliskiren.

Clinical Trial Conditions for Tekturna

Condition Name

Condition Name for Tekturna
Intervention	Trials
Hypertension	6
Diabetes	2
Diabetes Mellitus	2
Macroalbuminuric Diabetic Nephropathy	1

Condition MeSH

Condition MeSH for Tekturna
Intervention	Trials
Hypertension	6
Kidney Diseases	3
Diabetes Mellitus	3
Diabetic Nephropathies	2

Clinical Trial Locations for Tekturna

Trials by Country

Trials by Country for Tekturna
Location	Trials
United States	18

Trials by US State

Trials by US State for Tekturna
Location	Trials
Massachusetts	2
Minnesota	2
Michigan	2
Texas	2
New York	2

Clinical Trial Progress for Tekturna

Clinical Trial Phase

Clinical Trial Phase for Tekturna
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Tekturna
Clinical Trial Phase	Trials
Terminated	8
Completed	5
Withdrawn	3

Clinical Trial Sponsors for Tekturna

Sponsor Name

Sponsor Name for Tekturna
Sponsor	Trials
Novartis	7
Novartis Pharmaceuticals	3
Texas Tech University Health Sciences Center	2

Sponsor Type

Sponsor Type for Tekturna
Sponsor	Trials
Other	22
Industry	11
NIH	2

Tekturna Market Analysis and Financial Projection

Last updated: April 24, 2026

TEKTURNA (aliskiren) Clinical Trials Update, Market Analysis, and Projection

What is TEKTURNA and what is its current commercial position?

TEKTURNA is aliskiren, an oral direct renin inhibitor (DRI). In the U.S., TEKTURNA is marketed by Novartis as a renin inhibitor for hypertension. The drug’s modern commercial footprint has been constrained by safety/regulatory actions and changes in guideline preferences away from renin inhibitor class therapies.

Regulatory pivot points that shaped the market

• 2012: FDA issued key safety communications restricting use of aliskiren with ACE inhibitors or ARBs in patients with diabetes or renal impairment (increased risk of adverse outcomes). (FDA safety communications; see sources [1], [2])
• 2012-2014: Additional restrictions and trial program impacts followed across major markets, tied to renal/cardiovascular risk findings in high-risk populations.
• 2023-2024: Core TEKTURNA commercial activity in mature markets is largely “survival” prescribing for remaining eligible patients, with most growth now absent. The business question is no longer expansion, but sustaining value and limiting liability.

Portfolio context

• The therapy is a single active ingredient product (aliskiren) with historical indications concentrated in hypertension and use patterns affected by combined-therapy restrictions.

---

What do the major clinical trial outcomes say about TEKTURNA risk-benefit?

TEKTURNA’s clinical record is dominated by hypertension efficacy plus several large outcome trials that shifted the risk-benefit view, particularly when aliskiren was combined with ACE inhibitors or ARBs, or used in high-risk populations.

Which pivotal efficacy and outcomes trials define the TEKTURNA evidence base?

The pivotal outcomes narrative comes from large randomized programs:

1. ALTITUDE (high-risk type 2 diabetes)

   • Design: Aliskiren added to ACE inhibitor or ARB in patients with type 2 diabetes and additional risk factors.
   • Result: The trial was terminated early due to safety concerns and lack of benefit on primary outcomes. (Sources [3], [4])

2. ATMOSPHERE and related DRI outcome studies

   • Multiple DRI trials across renal/cardiovascular endpoints converged on the same theme: limited incremental benefit with heightened risk signals in combination regimens.

What endpoints moved and why did that matter commercially?

Across combination regimens (aliskiren + ACE inhibitor or ARB), the evidence pattern includes:

• Increased adverse events and kidney-related safety signals in high-risk cohorts.
• No durable, clinically meaningful reduction in major cardiovascular outcomes compared with standard of care.

These outcomes drove guideline and regulatory restriction, cutting off the broadest potential market expansion pathways.

---

Clinical trials update: what is active versus de-risked now?

For TEKTURNA, most clinical energy has shifted from large outcomes programs to:

• Label-constrained use within existing indications and populations.
• Post-marketing safety monitoring and pharmacovigilance.
• Competitive positioning through combination antihypertensive regimens available from other classes.

Trial activity today

• No major globally recognized new phase-3 cardiovascular outcome program is associated with aliskiren in the current period in the public record used by mainstream reporting (EMA/FDA label updates and large trial registries).
• Commercially, that means TEKTURNA’s market trajectory depends on generic substitution, guideline drift, and regulatory compliance rather than on new clinical evidence.

(Outcome trial details are reflected in FDA and peer-reviewed summaries; see sources [1]-[4].)

---

How do regulatory actions affect TEKTURNA’s market access and prescribing?

What restrictions did regulators impose on combination use?

FDA communications in 2012 limited aliskiren in combination with ACE inhibitors or ARBs for high-risk groups:

• Patients with diabetes: avoid combination therapy.
• Patients with renal impairment: avoid combination therapy. (Source [1], [2])

Commercial impact

• This directly reduces prescribing scenarios in which aliskiren could have replaced or added to first-line regimens.
• It also increases the compliance burden for prescribers and payers, which can reduce formulary friendliness.

---

Market analysis: where does TEKTURNA fit in hypertension treatment now?

What is the competitive landscape for aliskiren in hypertension?

The hypertension market is dominated by:

• ACE inhibitors
• ARBs
• Calcium channel blockers
• Thiazide-type diuretics
• Fixed-dose combinations

DRIs face a structural hurdle:

• The class’s outcome record is weaker than mainstream alternatives when used in combination strategies that match real-world guideline pathways.

What does that mean for TEKTURNA demand?

Demand growth is constrained by three factors:

1. Safety restriction compliance
2. Guideline preference
3. Generic availability and price compression (where applicable in each jurisdiction)

As a mature product, TEKTURNA’s market economics behave like a “hold and harvest” asset rather than a growth driver.

---

Market projection: TEKTURNA revenues and volume outlook

What is the base-case projection for TEKTURNA performance?

Because public, consolidated company revenue numbers for TEKTURNA alone are not provided in the sources cited here, a defensible projection must be expressed as market behavior rather than exact revenue forecasts.

Base-case behavior (2024-2028)

• Volume: Flat-to-declining versus population growth, driven by generic competition and shrinking prescriber adoption in high-risk combinations.
• Net price: Down or flat due to generic substitution and payer pressure.
• Share: Gradual erosion as standard classes remain default choices and remaining utilization shifts toward guideline-aligned regimens.

Scenario framework (directional, regulatory-driven)

• Bull case: Stable or modest decline only. Requires fewer label restrictions tightening and steady payer coverage in remaining approved populations.
• Base case: Steady decline. Driven by continued substitution and aging of treated cohorts.
• Bear case: Faster decline if safety messaging leads to additional restriction interpretations or payer narrowing.

This directional outcome is anchored to the ALTITUDE early termination and subsequent FDA restrictions that curtailed broad combination use. (Sources [1], [2], [3].)

---

IP and product longevity: does TEKTURNA have new defensible runway?

What is the practical patent-life question for investors now?

TEKTURNA is a legacy branded product. For investors, the question is less about new clinical runway and more about:

• Generic penetration pace by jurisdiction
• Remaining exclusivity on formulation/device packaging (if any)
• Entry of biosimilar-like analogs does not apply; this is small molecule competition

Public clinical and regulatory evidence in the cited record does not indicate a new late-stage exclusivity expansion through novel indications.

---

Where are the biggest upside pockets for TEKTURNA commercialization?

What use-cases remain most realistic?

Within regulatory constraints, TEKTURNA can still find room in narrower segments such as:

• Patients who cannot tolerate ACE inhibitors or ARBs
• Hypertension populations where prescribers select aliskiren rather than other classes after contraindications

However, this is limited by the class’s outcome record and by the ease of prescribing alternative generics.

---

Key Takeaways

• TEKTURNA (aliskiren) is a mature DRI with market constraints set by safety outcomes and regulatory restrictions, especially regarding combination therapy with ACE inhibitors/ARBs in diabetes and renal impairment. (FDA communications [1], [2])
• ALTITUDE and related outcome evidence drove early termination and weakened the class’s justification for broad guideline adoption. (Sources [3], [4])
• Current market direction is best modeled as flat-to-declining with price compression and prescribing migration to dominant antihypertensive classes.
• Near-term “clinical update” value is limited because the evidence base is dominated by legacy outcome trials rather than new phase-3 programs in the cited record.
• The most realistic upside is constrained to niche use where ACE/ARB intolerance exists and regulatory compliance is maintained.

---

FAQs

1) What triggered TEKTURNA label restrictions in the US?

FDA issued safety communications in 2012 restricting aliskiren combination use with ACE inhibitors or ARBs in patients with diabetes and in patients with renal impairment due to increased adverse outcomes. [1], [2]

2) What was the key outcome of the ALTITUDE trial?

ALTITUDE was terminated early because adding aliskiren to ACE inhibitor or ARB therapy did not improve outcomes and raised safety concerns. [3], [4]

3) Does TEKTURNA still have a hypertension indication today?

Yes, TEKTURNA is historically indicated for hypertension, but real-world use is affected by regulatory restrictions on combination therapy in high-risk groups. [1], [2]

4) Why did aliskiren lose commercial momentum versus ACE inhibitors and ARBs?

The class’s outcome record in combination regimens and high-risk cohorts led to restrictions that narrowed eligible use cases and reduced guideline pull. [1]-[4]

5) What is the market projection direction for TEKTURNA?

Base-case behavior is flat-to-declining due to guideline preference for other classes, safety-driven prescribing constraints, and mature-market pricing pressure. [1]-[4]

---

References

[1] U.S. Food and Drug Administration. (2012). FDA Drug Safety Communication: Aliskiren (Tekturna) should not be used with certain drugs in patients with diabetes or kidney disease. FDA.
[2] U.S. Food and Drug Administration. (2012). Safety-related label changes for aliskiren (Tekturna) based on findings from ALTITUDE. FDA.
[3] Parving, H.-H., Brenner, B. M., McMurray, J. J. V., et al. (2012). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): terminated early due to increased adverse outcomes and no benefit. The New England Journal of Medicine.
[4] Makani, H., Bangalore, S., Romero, J. R., et al. (2013). Meta-analysis and outcome synthesis on aliskiren in combination regimens and cardiovascular-renal endpoints. Annals of Internal Medicine / peer-reviewed synthesis.